dc.contributor
Institut Català de la Salut
dc.contributor
[Vivanco-Hidalgo RM, Martinez E, Roman-Viñas R] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain. [Molina I, Sánchez-Montalvá A] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fibla J] Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain. Institut de Recerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, Lleida, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Vivanco-Hidalgo, Rosa M.
dc.contributor.author
Martinez, Elisenda
dc.contributor.author
Roman-Viñas, Ramón
dc.contributor.author
Sánchez Montalvá, Adrián
dc.contributor.author
Fibla, Joan
dc.contributor.author
Molina Romero, Israel
dc.date.accessioned
2025-10-24T10:30:46Z
dc.date.available
2025-10-24T10:30:46Z
dc.date.issued
2021-07-19T12:58:51Z
dc.date.issued
2021-07-19T12:58:51Z
dc.date.issued
2021-03-04
dc.identifier
Vivanco-Hidalgo RM, Molina I, Martinez E, Roman-Viñas R, Sánchez-Montalvá A, Fibla J, Pontes C, Velasco Muñoz C; Real World Data Working Group. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. Euro Surveill. 2021 Mar;26(9):2001202.
dc.identifier
https://hdl.handle.net/11351/6182
dc.identifier
10.2807/1560-7917.ES.2021.26.9.2001202
dc.identifier
000626069000003
dc.identifier.uri
https://hdl.handle.net/11351/6182
dc.description.abstract
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina
dc.description.abstract
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cloroquina; Hidroxicloroquina
dc.description.abstract
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Chloroquine; Hydroxychloroquine
dc.description.abstract
Background Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). Aim To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. Methods We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. Results We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83–1.44; p = 0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; p = 0.10). Conclusions Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.
dc.description.abstract
No funding was obtained for this study. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
dc.format
application/pdf
dc.publisher
European Centre for Disease Prevention and Control
dc.relation
Eurosurveillance;26(9)
dc.relation
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2001202
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
COVID-19 (Malaltia) - Catalunya
dc.subject
Medicaments antivírics - Efectes secundaris
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::incidencia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.title
Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
